93 results about "Secretory cell" patented technology

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

The invention discloses an application of enzymatic casein in promotion of porcine endocrine cell proliferation, belongs to the technical field of animal nutrition and feed, and provides an application of enzymatic casein in promotion of porcine endocrine cell proliferation, which does not aim at diagnosis and treatment of diseases. The invention provides a method for promoting pig endocrine cell proliferation by using casein enzymolysis. The method comprises the following steps: adaptively feeding pigs with daily ration with the crude protein content of 13% for 7 days; mixing the daily ration with the crude protein content of 13% with the enzymolysis casein according to the mass ratio of 95.5: 4.5 to obtain the daily ration containing the enzymolysis casein, and feeding twice a day for 28 days. According to the invention, a certain proportion of casein hydrolysate is added into the feed to regulate and control microbe composition of small intestinal mucosa of growing pigs, so that proliferation of small intestinal endocrine cells is further regulated, the secretion level of gastrointestinal hormone is increased, the gastrointestinal transport function of animals is finally enhanced, the absorption of nutrient substances is accelerated, and the growth performance of the pigs is improved.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The invention relates to the field of microorganisms, in particular to lactobacillus plantarum TRT-01 with anti-inflammatory and bacteriostatic functions as well as a preparation method and application of the lactobacillus plantarum TRT-01, the lactobacillus plantarum TRT-01 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32237, and the preservation date is October 17, 2024. The plant lactobacillus has broad-spectrum bacteriostatic activity on 10 pathogenic bacteria such as helicobacter pylori, streptococcus mutans and the like, and can regulate Th1 / Treg immune balance and relieve inflammatory response by inducing dendritic cells to secrete cell factors IL-10 and IL-12, inducing T cells to secrete cell factors TGF-beta and IFN-gamma and inhibiting secretion of cell factors IL-6 at the same time. Therefore, the plant lactobacillus TRT-01 disclosed by the invention can be used for preparing a composition with anti-inflammatory and bacteriostatic effects, is suitable for the fields of medicines, foods, health-care products and the like, and is particularly suitable for developing a microbial preparation with a probiotic effect.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the field of biological tissue and organ 3D printing, and discloses a biomimetic valve type organ obtained through 3D biological printing and corresponding 3D printing ink, and the 3D printing ink for forming the biomimetic valve type organ is biological ink obtained by dispersing a photocurable biological material in a phosphate buffer solution, then adding a photoinitiator solution, uniformly mixing, discharging bubbles, and then adding cell spheres to obtain the photoinitiator. The cell ball is a valve interstitial cell ball with a micron-scale diameter, which is obtained by culturing valve interstitial cells by using an agarose mold in the presence of a cell culture medium; and the agarose mold is provided with micron-scale holes. According to the method, the loading mode of the valvular interstitial cells is improved, the cell balls serve as the minimum printing unit, damage to the cells in the 3D printing period is avoided, the interaction between the cells is enhanced, the cells are stimulated to secrete the extracellular matrix, and extracellular matrix remodeling is completed.

The present disclosure relates to a method for preparing a respiratory organoid by proliferating and differentiating respiratory epithelial cells. Unlike the conventional respiratory organoids in which epithelial cells existing in the apical region of the respiratory organ are generated on the interior of the organoid, the respiratory organoid of the present disclosure is shown in a form in which ciliated structures, which are epithelial cells, are located in the outer layer of the organoid, secretory cells are present on the interior, and basal stem cells existing at the base of respiratory tissue are also present on the interior of the organoid. It has a form similar to an actual respiratory tissue, and it was observed that the epithelial cells exhibited normal function, such as motility of ciliated cells. Therefore, when an organoid is prepared using the preparation method of the present disclosure, a respiratory organoid that can well mimic actual tissue can be prepared.

Provided is a humanized CD19 single-chain variable fragment (scFv) having a mutation of valine to glycine in CDR1, comprising VH having the amino acid sequence of SEQ ID NO: 6 and VL having the amino acid sequence of SEQ ID NO: 5. Also provided is a CD19 chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv), (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized CD19-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

Disclosed herein are immune activating conjugates with immunogenic carrier proteins coupled to hapten and immune cell receptor agonist-containing polymers. The polymers promote uptake by B cells, enabling intracellular immune cell receptor activation and formation of long-lived antibody-secreting cells. In some aspects, disclosed herein in is a conjugate comprising an immunogenic carrier protein coupled to a polymer, wherein the polymer includes: i) a first monomeric unit comprising a first monomer coupled to a hapten, and ii) a second monomeric unit comprising a second monomer coupled to an immune cell receptor agonist.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The invention relates to an up-regulation Nuak1 immune cell and application thereof, and particularly provides an over-expression Nuak1 immune cell and application thereof in preparation of drugs for treating diseases. Specifically, up-regulation of the Nuak1 in immune cells can significantly improve the toxicity, proliferative activity and cytokine or GZMB secretion ability of the immune cells, and further has the effect of enhancing tumor treatment.

The invention discloses a bioactive material for inducing blood vessel and osteogenesis and a preparation method and application of the bioactive material, and belongs to the technical field of tissue engineering, the bioactive material for inducing blood vessel and osteogenesis comprises Schneid membrane mesenchymal stem cells and platelet-rich fibrous protein membranes, the Schneider membrane mesenchymal stem cells are loaded on the surface of the platelet-rich fibrin membrane, and the Schneider membrane mesenchymal stem cells have the strong membrane forming characteristic when cultured in vitro, can gather and proliferate massively on the surface of PRF, continuously secrete an extracellular matrix to wrap the PRF and replace an original stent along with degradation of the PRF, so that the Schneider membrane mesenchymal stem cells can be used for preparing the stent. The SMMSCs can continuously release bioactive factors, so that the osteogenic function period of the material is prolonged. In addition, the PRF membrane loaded with SMMSCs widens the application range of PRF, can be directly used as a bone grafting filling material, and also can be used as a periosteum-like guided tissue regeneration barrier membrane.

Provided in the present application are an SSTR2-targeting peptide, and an SSTR2-targeting peptide-drug conjugate and the use thereof. The peptide / peptide drug conjugate can be used for the diagnosis, prevention, inhibition or treatment of cancers, especially solid tumors derived from neuroendocrine cells, such as neuroendocrine tumors in the digestive system such as the stomach, intestines and pancreas, and small cell lung cancer.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting NKG2DL and secreting IL-15 and a preparation method thereof, the method comprises the step of infecting a T cell with a recombinant lentivirus, and the recombinant lentivirus contains a nucleic acid molecule of a chimeric antigen receptor encoding NKG2D and IL-15 or is prepared through an expression vector containing the nucleic acid molecule. The CAR-T cell expresses a chimeric antigen receptor targeting NKG2DL and can secrete a cell factor IL-15, the proliferation and effector functions of the CAR-T cell are promoted, and the killing activity on tumors is enhanced.

The invention relates to a functionalized cartilage tissue repair material as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering. The invention aims to solve the problems that the existing decalcified bone matrix is insufficient in cartilage induction in cartilage repair, and is easy to cause blood vessel ingrowth and fibrosis repair. The preparation method comprises the following steps: inoculating cartilage cells on a three-dimensional porous frame structure carrier, carrying out in-vitro dynamic pre-culture to enable the cartilage cells to secrete an extracellular matrix, and carrying out decellularization treatment to obtain the functionalized cartilage tissue repair material retaining the cartilage specific matrix. The material has a suitable pore structure and abundant II-type collagen deposition, can effectively promote chondrocyte differentiation and hyaline cartilage regeneration, inhibits blood vessel ingrowth, maintains a cartilage vascular-free microenvironment, significantly improves the structure and function reconstruction effect of cartilage defect repair, and has good biocompatibility and clinical transformation potential.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. A preferred co-stimulatory domain is CD28 or 41-BB. The humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The present application relates to the technical field of biological medicine, in particular to an anti-CEACAM5 antibody and application thereof, the anti-CEACAM5 antibody has the following technical features: the heavy chain variable region includes CDR-H1 with the amino acid sequence shown in SEQ ID No.1, CDR-H2 with the amino acid sequence shown in SEQ ID No.2 and CDR-H3 with the amino acid sequence shown in SEQ ID No.3.The anti-CEACAM5 antibody has high affinity, is used as an antigen binding domain to construct a chimeric antigen receptor, and utilizes the chimeric antigen receptor to prepare a CAR-T cell, the CAR-T cell has killing activity on tumor cells positive for CEACAM5, and after co-culturing with CEACAM5-positive cells, the CAR-T cell can efficiently secrete the cytokine IFN-gamma, the nanobody can be effectively applied to immunotherapy, and has important significance for developing tumor treatment drugs.

Neuroendocrine tumors (NETs) are highly heterogeneous tumors derived from neuroendocrine cells. The synaptic vesicle 2 (SV2) protein is a novel marker of NETs and has three subtypes of SV2A, SV2B and SV2C, the SV2C structure is more stable than the other two subtypes, and the maximum cavity ring L4 is the most important binding region with toxins. The nano antibody of the extracellular soluble part L4 of the SV2 is obtained by screening through a phage display technology, the obtained nano antibody is labeled by fluorescein, chemical toxin small molecules or nuclide to prepare a probe molecule, and the result can specifically bind to neuroendocrine tumor cells. The invention provides a nano antibody of an extracellular soluble part L4 of SV2. The nano antibody can be applied to preparation of a preparation for diagnosing and treating neuroendocrine tumors.

The invention belongs to the field of biological medicine, and relates to a CAR-T cell targeting NKG2DL and secreting IL-10 and a preparation method thereof, the method comprises the step of infecting a T cell with a recombinant lentivirus, and the recombinant lentivirus contains a nucleic acid molecule of a chimeric antigen receptor encoding NKG2D and IL-10 or is prepared through an expression vector containing the nucleic acid molecule. The CAR-T cell expresses a chimeric antigen receptor targeting NKG2DL and can secrete a cell factor IL-10, the proliferation and effector functions of the CAR-T cell are promoted, and the killing activity on tumors is enhanced.

The present application belongs to the field of biomedical technology, and particularly relates to a cell-derived extracellular matrix and a preparation method and application of a cell culture plate coated with the cell-derived extracellular matrix. The present application cultures human astrocytes in a cell culture plate, and makes the human astrocytes secrete extracellular matrix. After the human astrocytes are added into a cell lysate for cell removal treatment, nucleic acid fragmentation treatment is performed to obtain the cell-derived extracellular matrix. The present application has relatively simple operation, short time period, and can realize batch production of extracellular matrix without external virus carrying and stable components. The obtained cell-derived extracellular matrix is resistant to storage, has good stability, is highly similar to a natural brain environment when coated on a cell culture plate, has good biocompatibility with cells, can be applied to tissue repair and regeneration as an ideal biomedical material, can regulate the progress and efficiency of human dermal fibroblast HDF transdifferentiation into neurons, and can obtain in-vitro survival neurons.

The present invention relates to the field of cell culture and application technology, and specifically discloses a method for constructing cell-containing autocrine ECM cell meat, CEF cells are inoculated in medium No. 1 and proliferated and cultured at a speed of 110-120rpm; when the cell density reaches 1.4E6-1.5E6, it is replaced with medium No. 2, and adjusted to variable speed culture: 40-45rpm, 5-6min; 0rpm, 1-1.2h, 24 cycles, and 100-200um suspended cell aggregates are obtained after 20-24h of variable speed culture; then the speed is adjusted to 55-60rpm constant speed culture, medium No. 2 is replaced once a day, cultured for 4-6 days, and 450-500um autocrine ECM cell meat is harvested. The present invention can obtain 450-500um autocrine ECM cell meat, the cell viability is above 90%, and it can autosecrete ECM.

The invention belongs to the field of antibodies, and particularly relates to a bispecific antibody and application thereof. The bispecific antibody comprises a first antigen binding region and a second antigen binding region, wherein the first antigen binding region has HLA-G binding activity; and a second antigen binding region, the second antigen binding region having CD3 binding activity; wherein the first antigen binding region comprises an anti-HLA-G antibody, the anti-HLA-G antibody comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-3 or an amino acid sequence in a conservative modification form of the at least one selected from SEQ ID NO: 1-3. The bispecific antibody can be combined with CD3 and HLA-G so as to promote T cell activation, proliferation and cytokine secretion and effectively promote PBMC to kill tumor cells, and the bispecific antibody has good anti-cancer activity; and the bispecific antibody has low binding activity with T cells and high binding activity with tumor cells, and has good clinical application value and drug development value.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

The present invention belongs to the field of biomedicine, and relates to a CAR-T cell expressing a dual-targeted CD38 and BCMA serial-parallel hybrid chimeric antigen receptor and secreting IL-10, and a preparation method thereof, the method comprising infecting T cells with a recombinant lentivirus, the recombinant lentivirus comprising a nucleic acid molecule encoding a dual-targeted CD38 and BCMA serial-parallel hybrid chimeric antigen receptor comprising IL-10, or obtained by an expression vector comprising the nucleic acid molecule. The CAR-T cell of the present invention expresses a serial-parallel hybrid CD38-BCMA-CAR and CD38-CAR, and can secrete the cytokine IL-10, promote the proliferation and effector function of CAR-T cells, and enhance anti-tumor activity.

Provided is a technique capable of evaluating a property of a secretion product with high accuracy.　Specifically provided are a secretion product evaluation method and others, the secretion product evaluation method comprising: a positional information identification step for identifying positional information of at least one secretory cell and at least one antigen-holding particle on the basis of optical information relating to a carrier that holds the secretory cell and the antigen-holding particle; a secretion product information acquisition step for acquiring information relating to a secretion product that binds to a binding target molecule held by the secretory cell and the antigen-holding particle; and a secretion product evaluation step for evaluating a property of the secretion product on the basis of the positional information and the information relating to the secretion product.

The invention provides a culture solution for culturing NK (Natural Killer) cells and a technology for amplifying the NK cells in vitro, and belongs to the technical field of immunobiology. The culture solution comprises an NK cell culture solution, namely an RPMI-1640 culture solution, fetal calf serum, L-glutamine, IL-2 and a polypeptide composition, namely polypeptide CT-K3K7NK cell promoting peptide. When the culture solution is used for culturing the NK cells obtained from the elderly individuals, the multiplication capacity, the cell killing activity and the cell factor IFN-gamma secretion capacity of the NK cells can be remarkably improved. Therefore, the invention provides a new scheme and thought for solving the problem of insufficient proliferation and killing activity of the NK cells of the elderly individuals in the autoculture process, and has a wide application prospect in the field of senescence-related immunotherapy.

The present invention relates to a method for producing respiratory organoids by proliferating and differentiating respiratory epithelial cells. [Solution] Unlike conventional respiratory organoids in which epithelial cells present at the apical end of the respiratory tract develop inside the organoid, the respiratory organoid of the present invention has a morphology in which the ciliated structure, which is made up of epithelial cells, is located in the outer layer of the organoid, secretory cells are located inside, and stem cell-like basal cells present at the base of the respiratory tissue are also located inside the organoid. This morphology is similar to that of actual respiratory tissue and has been observed to exhibit normal functions of epithelial cells, such as the motility of ciliated cells. Therefore, by manufacturing organoids using the manufacturing method of the present invention, it is possible to manufacture respiratory organoids that can accurately mimic actual tissue.

The present disclosure provides an antibody capture complex and a method for capturing a target antibody secreted by an antibody-secreting cell. The present disclosure provides an antibody capture complex comprising a first member of a binding pair linked to an antibody capture molecule, the first member of the binding pair being capable of binding to a second member of the binding pair, the antibody capture molecule being capable of binding to a target antibody, and the target antibody being secreted by an antibody-secreting cell. In some embodiments, when the second member of the binding pair is biotin and the first member of the binding pair is streptavidin, the antibody capture molecule does not bind to the kappa light chain of the target antibody.